Provided by Tiger Trade Technology Pte. Ltd.

Cemex SAB de CV

12.20
+0.25002.09%
Post-market: 12.250.0500+0.41%19:58 EST
Volume:6.26M
Turnover:75.76M
Market Cap:17.70B
PE:13.15
High:12.24
Open:11.99
Low:11.90
Close:11.95
52wk High:13.35
52wk Low:4.89
Shares:1.45B
Float Shares:1.45B
Volume Ratio:0.71
T/O Rate:0.43%
Dividend:0.09
Dividend Rate:0.73%
EPS(TTM):0.9275
EPS(LYR):0.6390
ROE:3.10%
ROA:2.23%
PB:1.33
PE(LYR):19.09

Loading ...

RBC Capital Sticks to Its Hold Rating for Cemex SAB (CX)

TIPRANKS
·
Feb 06

Cemex SAB de CV : HSBC Cuts to Hold From Buy; Raises Target Price to $12.8 From $10

THOMSON REUTERS
·
Feb 06

Cemex SAB de CV Is Maintained at Sector Perform by Scotiabank

Dow Jones
·
Feb 06

Mexico's Cemex Posts 4Q Ebitda Growth, Net Loss

Dow Jones
·
Feb 05

Cemex Q4 EPS $(0.24) Misses $0.02 Estimate, Sales $4.180B Beat $3.961B Estimate

Benzinga
·
Feb 05

Only Small Group of Banks Are Turning AI into Revenue, New Research Finds

prnewswire
·
Feb 05

Earnings Flash (CX) Cemex Posts Q4 Sales $4.18B

MT Newswires Live
·
Feb 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 05

Table: CX Technology Corp Jan Rev NT$226.9M Vs NT$195.4M

Dow Jones
·
Feb 04

8×8 ‘accelerates AI-powered CX transformation across industries’

TIPRANKS
·
Feb 04

Cemex price target raised to $15 from $12 at Barclays

TIPRANKS
·
Jan 27

Analysts Offer Insights on Materials Companies: MP Materials (MP) and Cemex SAB (CX)

TIPRANKS
·
Jan 26

AI-Powered Customer Experience Platform Toku Opens Trading on SGX with Strong Debut as First IPO of 2026

prnewswire
·
Jan 22

AI CX Platform Toku Lists on SGX Catalist to Fuel Global Expansion

TIPRANKS
·
Jan 22

Cemex call volume above normal and directionally bullish

TIPRANKS
·
Jan 22

Singapore's AI-Powered Customer Experience Platform Toku Launches First SGX IPO of 2026

prnewswire
·
Jan 14

Changan Mazda plans to launch CX-6e electric SUV in Europe, Australia, and New Zealand

CnEVPost
·
Jan 13

Will Rising Interest in AI CX Tools Change Sprinklr's (CXM) Unified Platform Narrative?

Simply Wall St.
·
Jan 11

CytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target

TIPRANKS
·
Jan 09

Table: CX Technology Corp Dec Rev NT$220.3M Vs NT$186.1M

Dow Jones
·
Jan 08